Marina D. Kaymakcalan

Author

Also Known As

M D Kaymakcalan, M. Kaymakcalan, M.D. Kaymakcalan, Marina D Kaymakcalan, Marina D. Kaymakcalan, Marina Dusevic Kaymakcalan, Marina Kaymakcalan

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Brigham and Women's Hospital Pfizer (United States)University of Genoa University of Calgary

About

Marina D. Kaymakcalan is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	254
2	Immunology	2	2	83
3	Pharmacology	2	2	87
4	Nephrology	1	1	15
5	Surgical Oncology	1	1	43

Marina D. Kaymakcalan

Publications

882

Citations

H-Index

Page 1

	Year	Citations
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway Ole‐Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Cancer	2014	202
Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Rana R. McKay, Gustavo E. Rodriguez, Xun Lin, Clinical Cancer Research	2015	132
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma Aly‐Khan A. Lalani, Wanling Xie, David A. Braun, European Urology Oncology UrologyAntibioticsAntibiotic UseMedicineAntibiotic Adjuvant	2019	94
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study André P. Fay, Sabina Signoretti, Marcella Callea, Journal for ImmunoTherapy of Cancer	2015	90
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma Sarah Abou Alaiwi, Wanling Xie, Amin H. Nassar, Journal for ImmunoTherapy of Cancer	2020	82
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma Bradley A. McGregor, Aly‐Khan A. Lalani, Wanling Xie, European Journal of Cancer OncologyGenitourinary CancerMedicineImmunologyImmune Checkpoint Inhibitor	2020	68
Statins and survival outcomes in patients with metastatic renal cell carcinoma Rana R. McKay, Xun Lin, Laurence Albigès, European Journal of Cancer	2015	46
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Aly‐Khan A. Lalani, Rana R. McKay, Xun Lin, Clinical Genitourinary Cancer UrologySurgical OncologySurvival OutcomesGenitourinary CancerMedicine	2017	43
Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Marina D. Kaymakcalan, Wanling Xie, Laurence Albigès, Cancer	2015	35
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study Nieves Martínez Chanzá, Wanling Xie, Majd Issa, Journal for ImmunoTherapy of Cancer	2020	31

Page 1